STOCKS TELEGRAPH

Tag: Nabriva Therapeutics

  • What’s the latest about Nabriva Therapeutics (NBRV)?

    What’s the latest about Nabriva Therapeutics (NBRV)?

    Nabriva Therapeutics (NBRV) stock is surging in the pre-market on Wednesday, March 17, 2021. It has gained 17.19% as of this writing. The stock went down 8.57% on Tuesday, March 16, 2021.

    Latest Development

    On March 16, 2021,Nabriva Therapeutics announced its results from a post-hoc analysis of clinical data from the pivotal Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 clinical trial has been published in The Journal of Emergency Medicine 

    The trial results revealed that the patients avoided hospitalization by taking XENLETA for 5 days. XENLETA was demonstrated in patients with moderate to severe community-acquired bacterial pneumonia (CABP). XENTLETA was approved by the FDA in August 2019 and the first IV and oral antibiotic with a novel mechanism of action approved by the FDA in nearly two decades.

    Recent Financial results

    On March 12, 2021, NBRV announced its financial results for the fourth quarter and the year ended December 31, 2020.

    Q4 Financial Highlights

    • NBRV revenue for the reported quarter was $2.5 million.
    • Research and development expenses were $2.8 million
    • Selling, general and administrative expense were $17.5 million

    Full-year Financial Highlights

    • NBRV revenue for the full-year 2020 was $5.0 million.
    • Research and development expenses were $15.1 million for the full year.
    • Selling, general and administrative expense were $55.3 million.
    • Nabriva had $41.4 million in cash and cash equivalents as of December 31 2020.

    NBRV Corporate Updates

    • On March 10, 2021, Steven Gelone, Pharm D, was selected by Nabriva’s Board as a new member to the board effective immediately.
    • On February 26, 2021, Daniel Dolan was appointed as Chief Financial Officer, he started working as CFO on March 13.

    NBRV Business Updates

    On March 1, 2021, Nabriva signed an agreement with investors for the purchase and sale of ordinary sharesfor aggregate net proceeds of $23.4 million.

    About NBRV

    Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. The company was founded in 2005 and is based in Ireland.

    The NBRV latest product XENLETAreceived U.S. Food and Drug Administration approval to treat CABP. The company is also working on also developing CONTEPO to treat urinary tract infections (cUTI), including acute pyelonephritis.

  • Biotech Roundup &The delivery of the Pfizer’s vaccine to U.S. – starts Today

    Biotech Roundup &The delivery of the Pfizer’s vaccine to U.S. – starts Today

    This weekend, the U.S. government is packaging millions of doses of the coronavirus vaccine from Pfizer and BioNTech for distribution to places around the country, a mammoth logistics task in favor of what could be the most difficult immunization campaign in history.

    In delivering the vaccine, which is delicate and needs careful care, FedEx and UPS would play key roles. At the terminal, shipments can gain preferential entry. If a plane arrives to land with vaccinations, other passenger flights may have to loop around to wait for their chance.

    The arrival of the first vaccines comes as the virus continues to rage through the USA, with more than 207,000 new cases identified on Saturday by authorities. That took the number to more than 16 million, the most in the world by far. For the first time on Wednesday, more than 3,000 deaths were reported, and the country’s number is nearing 300,000.

    vTv Therapeutics Inc. (NASDAQ:VTVT) shares were trading up 41.55% at $3.10 at the time of writing on Friday. The firm on November 25, 2020 announced common stock purchase agreement for up to $47 million with Lincoln Park Capital.

    vTv Therapeutics Inc. (NASDAQ:VTVT) share price went from a low point around $1.44 to briefly over $4.23 in past 52 weeks, though shares have since pulled back to $3.10. VTVT market cap has remained high, hitting $161.79M at the time of writing, giving it price-to-sales ratio of more than 7350.

    If we look at the recent analyst rating VTVT, H.C. Wainwright initiated coverage on VTVT shares with a Buy rating.

    aTyr Pharma Inc. (LIFE) last closed at $4.64, in a 52-week range of $2.13 to $7.62. The company on November 13, 2020 released third quarter results and provided a corporate update.

    ADiTx Therapeutics Inc. (ADTX) stock soar by 3.77% to $2.48. The firm reported on December 8, 2020, that it will present at the 13th annual LD Micro main event conference on Tuesday, December 15, 2020 at 11:00 AM EST / 8:00 AM PST.

    9 Meters Biopharma Inc. (NASDAQ:NMTR) Shares headed falling, lower as much as -11.75%.

    Iterum Therapeutics plc (NASDAQ:ITRM) rose 11.72% after gaining more than $0.1 on Friday. The biotechnology firm declared on December 7,2020, filing of US patent application based on favorable written opinion of the International Search Authority.

    Vaxart Inc. (VXRT) last closed at $7.44, in a 52-week range of $0.28 to $17.49.

    Catabasis Pharmaceuticals Inc. (CATB) stock soar by 14.51% to $2.21. The most recent rating by Wedbush, on November 02, 2020, is at a Neutral.

    Advaxis Inc. (NASDAQ:ADXS) Shares headed rising, higher as much as 3.56%. The company on November 27, 2020 reported the closing of $9.2 million public offering. The most recent rating by Barclays, on August 03, 2016, is at an Overweight.

    Xeris Pharmaceuticals Inc. (NASDAQ:XERS) rose 11.74% after gaining more than $0.48 on Friday following an announcement from the company that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon).

    Novavax Inc. (NVAX) last closed at $124.88, in a 52-week range of $3.65 to $189.40. The firm on December 9, 2020, declared the appointment of Margaret G. McGlynn, R. Ph. to its board as an independent director. Analysts have a consensus price target of $186.20.

    Corbus Pharmaceuticals Holdings Inc. (CRBP) stock soar by 1.52% to $1.34. The most recent rating by ROTH Capital, on September 08, 2020, is at a Neutral.

    Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares headed falling, lower as much as -1.23%. The most recent rating by Mizuho, on April 22, 2020, is at a Neutral.

    Novan Inc. (NASDAQ:NOVN) rose 1.10% after gaining more than $0.01 on Friday.

    Nabriva Therapeutics plc (NBRV) last closed at $2.44, in a 52-week range of $3.26 to $18.29. The company recently announced pricing of $15 million public offering.

    Salarius Pharmaceuticals Inc. (SLRX) stock drop by -31.34% to $0.92 after declaring that it has entered into agreements with several institutional and accredited investors to exercise of warrants for $3.5 million of gross proceeds to be used for ongoing development of Seclidemstat. The most recent rating by Ladenburg Thalmann, on April 27, 2020, is at a Buy.

  • Nabriva Therapeutics AG (NBRV) plunged following the announcement of a reverse share split

    Nabriva Therapeutics AG (NBRV) plunged following the announcement of a reverse share split

    Nabriva Therapeutics AG (NBRV) stock slid 2.49% to 3.850 in the early trading session following the announcement of the Company that it will divide its outstanding ordinary shares into 1-for-10 reverse shares, applicable for trading purposes on the Nasdaq Global Select Market as of the beginning of trading on the Nasdaq Global Select Market.

    At the Yearly Shareholders’ meeting on 29 July 2020, the shareholders of Nabriva Therapeutics agreed, before and subject to the decision by the Board of Directors of Nabriva Therapeutics, in its absolute discretion, that a reverse share split is necessary for the Company to comply with a minimum requirement of $1.00 per share under Nasdaq Listing Regulation 5450(a)(1) (Bid Price Rule).

    Every ten ordinary shares of $0.01 each of the Company authorized and unissued, authorized and approved share capital shall be combined into one ordinary share of $0.10 each, thus reducing the nominal value of the ordinary shares of the Company’s authorized and unissued, authorized and issued share capital from $0.10 each to $0.01 each. The Board of Directors of Nabriva Therapeutics then decided that the reverse stock split was appropriate for the Company to conform with the Bid Price Law.

    The ordinary shares of Nabriva Therapeutics will continue to trade under the name ‘NBRV’ on the Nasdaq Global Select Market. The current CUSIP number for the ordinary shares of Nabriva Therapeutics after the reverse stock split is G63637 113.

    The reverse stock split would decrease outstanding ordinary shares from approximately 150,8 million to about 15,08 million post-split shares. It will also minimize the number of outstanding ordinary shares from 1,0 billion to 100,0 million in proportion.

    The reverse stock split will also refer to ordinary shares issued when the remaining limited stock units, stock options, and warrants of Nabriva Therapeutics are exercised, with a proportionate rise, if appropriate, in the corresponding exercise prices.

    In conjunction with the reverse stock split, no ordinary fractional shares will be issued. Shareholders who would generally be entitled to accept a proportional cash bonus would be entitled to receive an ordinary fractional share.